Skip to main content
SpringerLink
Log in

Options for Treating Pain in Cancer Patients with Dysphagia

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Patients with chronic pain often develop dysphagia during the course of an advanced disease such as cancer. Opioids are the cornerstone of the management of cancer pain and are commonly administered orally. However, the oral route does not suit patients with dysphagia, who require alternative methods to administer analgesic drugs. Opioids given by parenteral or transdermal routes provide adequate pain control, being at least as efficacious as the oral route, but knowledge and experience in conversion ratios are mandatory when using these routes of administration. For breakthrough pain, transmucosal fentanyl preparations should be the preferred option and these can be given as needed due to the route of absorption. In addition, a new class of opioid formulations has been developed for use in dysphagic patients that are administered via nasogastric or enteral tubes while maintaining their sustained-release properties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baijens LW, Clavé P, Cras P, Ekberg O, Forster A, Kolb GF, et al. European Society for Swallowing Disorders—European Union Geriatric Medicine Society white paper: oropharyngeal dysphagia as a geriatric syndrome. Clin Interv Aging. 2016;11:1403–28.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Groher ME, Crary MA. Dysphagia. Clinical management in adults and children. 2nd ed. St. Louis: Elsevier; 2012.

    Google Scholar 

  3. Bressan V, Stevanin S, Bianchi M, Aleo G, Bagnasco A, Sasso L. The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: a systematic review. Cancer Treat Rev. 2016;45:105–19.

    Article  PubMed  Google Scholar 

  4. Dysphagia Ekberg O. Diagnosis and treatment. Berlin: Springer Science and Business Media; 2012.

    Google Scholar 

  5. Ferrero López MI, De la Rubia Ortí JE, Castellano Vela E, González Monte C, Sanchis-Bayarri Bernal V, Navarro Sanz R. Factors associated with mortality in patients with dysphagia help in making dietary and nutritional choices [in Spanish]. Nutr Hosp. 2014;31:820–8.

    PubMed  Google Scholar 

  6. Davies A, Bagg J, Laverty D, Sweeney P, Filbet M, Newbold K, et al. Salivary gland dysfunction (‘dry mouth’) in patients with cancer: a consensus statement. Eur J Cancer Care (Engl). 2010;19:172–7.

    Article  CAS  Google Scholar 

  7. Raj SX, Thronaes M, Brunelli C, et al. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer. 2014;22:1965–71.

    Article  PubMed  Google Scholar 

  8. Mercadante S. Cancer pain. Curr Opin Support Palliat Care. 2013;7:139–43.

    Article  PubMed  Google Scholar 

  9. Argoff CE, Kopecky EA. Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options. Curr Med Res Opin. 2014;30:2543–59.

    Article  CAS  PubMed  Google Scholar 

  10. Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Fusco F, et al. Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer. 2015;23:3249–55.

    Article  PubMed  Google Scholar 

  11. Kappelle WF, Siersema PD, Bogte A, Vleggaar FP. Challenges in oral drug delivery in patients with esophageal dysphagia. Expert Opin Drug Deliv. 2016;13:645–58.

    Article  CAS  PubMed  Google Scholar 

  12. Mercadante S, Fulfaro F. Alternatives to oral opioids for cancer pain. Oncology. 1999;13:215–20.

    CAS  PubMed  Google Scholar 

  13. Pergolizzi JV Jr, Taylor R Jr, Nalamachu S, Raffa RB, Carlson DR, Varanasi RK, et al. Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin. 2014;30:191–202.

    Article  PubMed  Google Scholar 

  14. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al.; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.

  15. Lane ME. The transdermal delivery of fentanyl. Eur J Pharm Biopharm. 2013;84:449–55.

    Article  CAS  PubMed  Google Scholar 

  16. Tassinari D, Drudi F, Rosati M, Maltoni M. Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review. Palliat Med. 2011;25:478–87.

    Article  PubMed  Google Scholar 

  17. Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008;11:492–501.

    Article  PubMed  Google Scholar 

  18. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev. 2013;(10):CD010270.

  19. Reddy A, Yennurajalingam S, Reddy S, Wu J, Liu D, Dev R, et al. The opioid rotation ratio from transdermal fentanyl to “strong” opioids in patients with cancer pain. J Pain Symptom Manag. 2016;51:1040–5.

    Article  Google Scholar 

  20. Mercadante S, Porzio G, Fulfaro F, Aielli F, Verna L, Ficorella C, et al. Switching from transdermal drugs: an observational “N of 1” study of fentanyl and buprenorphine. J Pain Symptom Manag. 2007;34:532–8.

    Article  CAS  Google Scholar 

  21. Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009;17:715–8.

    Article  PubMed  Google Scholar 

  22. Mercadante S, Porzio G, Ferrera P, Aielli F, Verna L, Tirelli W, et al. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther. 2009;31:2134–8.

    Article  CAS  PubMed  Google Scholar 

  23. Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer. 2007;15:441–4.

    Article  PubMed  Google Scholar 

  24. Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5:2–19.

    Article  CAS  PubMed  Google Scholar 

  25. Mercadante S. Opioid metabolism and clinical aspects. Eur J Pharmacol. 2015;769:71–8.

    Article  CAS  PubMed  Google Scholar 

  26. Pergolizzi JV Jr, Mercadante S, Echaburu AV, Van den Eynden B, Fragoso RM, Mordarski S, Euromed Communications Meeting, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin. 2009;25:1517–28.

    Article  CAS  PubMed  Google Scholar 

  27. Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010;11:484–9.

    Article  CAS  PubMed  Google Scholar 

  28. Sousa AM, de Santana Neto J, Guimaraes GM, Cascudo GM, Neto JO, Ashmawi HA. Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. Support Care Cancer. 2014;22:795–801.

    Article  PubMed  Google Scholar 

  29. Lasheen W, Walsh D, Mahmoud F, Sarhill N, Rivera N, Davis M, et al. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain. Palliat Med. 2010;24:9–16.

    Article  PubMed  Google Scholar 

  30. Radbruch L, Trottenberg P, Elsner F, Kaasa S, Caraceni A. Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. Palliat Med. 2011;25:578–96.

    Article  PubMed  Google Scholar 

  31. Nelson K, Glare P, Walsh D, et al. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manag. 1997;13:262–7.

    Article  CAS  Google Scholar 

  32. Elsner F, Radbruch L, Loick G, et al. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. J Palliat Med. 2005;8:743–50.

    Article  CAS  PubMed  Google Scholar 

  33. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer. 2002;95:203–8.

    Article  CAS  PubMed  Google Scholar 

  34. Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157:2657–63.

    Article  CAS  PubMed  Google Scholar 

  35. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;22(72):181–9.

    Article  Google Scholar 

  36. Fleming AB, Carlson DR, Varanasi RK, Grima M, Mayock SP, Saim S, et al. Evaluation of an extended-release, abuse-deterrent, microsphere-in-capsule analgesic for the management of patients with chronic pain with dysphagia (CPD). Pain Pract. 2016;16:334–44.

    Article  PubMed  Google Scholar 

  37. Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16:2142–51.

    Article  PubMed  Google Scholar 

  38. Lamb YN, Garnock-Jones KP, Keam SJ. Oxycodone DETERx® ER capsules: a review in severe, chronic pain. Drugs. 2016;76:1759–69.

    Article  CAS  PubMed  Google Scholar 

  39. McCarberg BH, Kopecky EA, O’Connor M, Marseilles A, Varanasi RK, Thompson C, et al. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia. Curr Med Res Opin. 2016;32:1975–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pain Relief and Supportive/Palliative Care, La Maddalena Cancer Center, Via San Lorenzo 312, 90146, Palermo, Italy

    Sebastiano Mercadante

Authors
  1. Sebastiano Mercadante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastiano Mercadante.

Ethics declarations

Conflict of interest

Sebastiano Mercadante has no conflicts of interest to declare.

Funding

No funding was received for this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mercadante, S. Options for Treating Pain in Cancer Patients with Dysphagia. Drugs 77, 629–635 (2017). https://doi.org/10.1007/s40265-017-0710-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0710-8

Keywords

Search

Navigation